Shir & Levitzki used the U87MGΔEGFR cell line that expresses a truncated form of epidermal growth factor receptor (EGFR) -Δ(2-7) EGFR. They observed that expression of a 39-nucleotide (nt) AS RNA complementary to the unique exon 1 to 8 junction activated PKR and caused selective death of cells harboring the truncated EGFR, both in vitro and in vivo but did not affect cells expressing wildtype EGFR. In addition, they showed that a lentiviral vector expressing the 39-nt AS sequence activated PKR and strongly inhibited glioblastoma growth in mouse brain when injected after tumor cell implantation.
This PKR-mediated killing strategy may be useful in treating many patients with cancers that express a unique RNA species, suggest the authors.
